Advertisement
Finance
Subscribe to Finance

The Lead

DPx Holdings B.V. Reaches Definitive Agreement to Acquire Gallus BioPharmaceuticals

August 28, 2014 11:55 am | News | Comments

DPx Holdings B.V., privately owned by JLL Partners and Royal DSM, has reached a definitive agreement to acquire all shares of Gallus BioPharmaceuticals, LLC, a contract manufacturing company specializing in biologics and current portfolio company of Ridgemont Equity Partners.

DuPont Fined $1.3M Over Series of West Virginia Chemical Leaks

August 28, 2014 8:20 am | by JOHN RABY, Associated Press | News | Comments

DuPont will pay a fine of $1.275M to settle a federal complaint over eight chemical releases...

Three Ways Insurers Can Discourage Sick from Enrolling

August 27, 2014 3:35 pm | by TOM MURPHY, AP Business Writer | News | Comments

Insurers can no longer reject customers with expensive medical conditions thanks to the health...

Amerigen Pharmaceuticals and Ningbo Menovo Pharmaceutical to Collaborate on Generics

August 27, 2014 12:04 pm | News | Comments

Under the terms of the agreement, Amerigen and Menovo will jointly develop products for Amerigen...

View Sample

FREE Email Newsletter

Report: Companion Testing Market Exceeded One Billion Dollars in 2013

August 27, 2014 9:11 am | News | Comments

The market for test and pharmaceutical pairs, known as companion diagnostics in the testing industry, has grown significantly. The global companion diagnostic market is valued at about $1.2 billion for 2013. This is up from $950 million in 2011, an increase of 12.5%.

Acura Pharmaceuticals Receives NIH Grant to Fund Limitx Novel Abuse Deterrent Technology

August 27, 2014 8:40 am | News | Comments

Acura Pharmaceuticals has been awarded a $300,000 grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx™ abuse deterrent technology.     

EMD Millipore Announces Strategic Alliance with Samsung BioLogics

August 26, 2014 2:34 pm | News | Comments

The alliance is intended to encompass a long-term supply agreement in which EMD Millipore will provide raw materials for biopharmaceutical manufacturing.                

Advertisement

Pfizer And Merck to Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen

August 26, 2014 8:35 am | News | Comments

Pfizer and Merck announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib with Merck’s investigational anti-PD-1 antibody pembrolizumab, in a Phase 1b clinical study evaluating the safety and tolerability of the combination in patients with ALK-positive advanced or metastatic non-small cell lung cancer.

Cilag GmbH International Acquires Covagen AG

August 25, 2014 8:41 am | News | Comments

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology platform.

VIVUS Acquires Topiramate-Related Patents From Janssen Pharmaceuticals

August 25, 2014 8:29 am | News | Comments

VIVUS today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.   

Roche to Buy InterMune for $8.3B

August 25, 2014 8:10 am | News | Comments

Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.                   

Allergan Reviews Meeting Requests in Takeover Bid

August 23, 2014 2:27 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Allergan Inc. is reviewing shareholder requests for a special meeting to consider replacing most of its board, a change fellow drugmaker Valeant Pharmaceuticals International Inc. is seeking as part of the hostile takeover attempt it's been waging since April. Allergan has repeatedly...

Advertisement

Business Leery of Alabama Ruling on Drug Warnings

August 23, 2014 11:30 am | by Jay Reeves - Associated Press - Associated Press | News | Comments

Business isn't buying the Alabama Supreme Court's attempt to limit the fallout from its decision saying brand-name drugmakers can be held liable for warnings on generic medication produced by other companies. A majority of justices signed off on an opinion that went to lengths last week to say...

Execution Drug Cost Quadruples for Texas Prisons

August 15, 2014 2:45 pm | by MICHAEL GRACZYK, Associated Press | News | Comments

The prison agency in the nation's busiest death penalty state paid $13,500 for its most recent batch of pentobarbital at a cost of $1,500 per vial, compared to $350 per dose spent last year.           

Allergan Acquires LiRIS® Program from TARIS Biomedical®

August 14, 2014 8:43 am | News | Comments

Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical's® lead program, LiRIS®, which is currently in Phase 2 trials for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).      

Dendreon Shares Sink After Company Warns of Debt Woes

August 13, 2014 8:26 am | by The Associated Press | News | Comments

The maker of the prostate cancer treatment Provenge said in a Securities and Exchange Commission filing that there is a "significant risk" it will not be able to repay or refinance $620 million in notes due in 2016.      

Ebola Drug Developer Sees Wild Swings in Stock Price Amid Outbreak

August 13, 2014 8:18 am | by Lauren Krugel, The Canadian Press | News | Comments

A Canadian company developing an experimental Ebola drug has seen its stock swing wildly in what one analyst describes as market overreaction to the latest headlines about the deadly outbreak.          

Advertisement

McKesson Settles Tennessee Vaccine Case for $18M

August 11, 2014 8:29 am | News | Comments

McKesson Corp. was required to ensure vaccines were maintained at proper temperatures by, among other things, setting electronic temperature monitors to detect when air temperature in the box reached certain levels.      

MannKind, Sanofi Enter Afrezza Deal Worth $925M

August 11, 2014 8:07 am | by The Associated Press | News | Comments

MannKind will receive $150 million upfront and then potential milestone payments of up to $775 million, depending on whether certain regulatory, development and sales targets are met. MannKind will make the supply of Afrezza, and Sanofi will be responsible for global commercial, regulatory and development activities.

U.S. Government Exercises $18.9M Contract Option for Emergent BioSolutions' Vaccinia Immune Globulin Intravenous Program

August 8, 2014 8:08 am | News | Comments

Emergent BioSolutions announced today that the Centers for Disease Control and Prevention (CDC) has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile (SNS).

AIDS Patients Fear Discrimination in ACA Exchange

August 7, 2014 8:47 am | by KELLI KENNEDY, Associated Press | News | Comments

Patient advocates say some insurance companies are making HIV and AIDS drugs unaffordable in plans issued through the Affordable Care Act by shifting much of the cost to customers. While the issue applies broadly to all patients with chronic illnesses that require expensive medication, HIV and AIDS advocates say they were the first to file a formal complaint with the government about pricing.

Mylan Second Quarter Profit Drops 30%

August 7, 2014 7:35 am | by The Associated Press | News | Comments

Mylan reported profit that declined by 30 percent in its second quarter, and missed analysts' expectations. The Canonsburg, Pennsylvania-based company said net income fell to $125.2 million, or 32 cents per share, from $177.7 million, or 46 cents per share.

Pfizer to Pay $35M to Settle Drug Marketing Case

August 6, 2014 4:38 pm | by The Associated Press | News | Comments

Pfizer will pay $35 million to resolve allegations by 42 states that its subsidiary, Wyeth Pharmaceuticals, illegally marketed an organ transplant drug for unapproved uses. The states' attorneys general said Wednesday that Wyeth, which Pfizer bought in 2009, trained sales representatives to prescribe Rapamune for uses other than preventing rejection of transplanted kidneys.

Why Fitting a Square Plug in a Round Hole is Profitable for Pharma and Most Likely Will Stay

August 6, 2014 8:50 am | by Girish Malhotra, PE; President, EPCOT International | Blogs | Comments

In 2005 I had raised a question about Batch or a Continuous Process: A Choice. At that time it seemed like a logical question and still is. However, I left part of the question unanswered. Missing was the discussion of components of pharma manufacturing, API manufacture and their formulations.

Despite FDA Woes Impax's Second Quarter 2014 Revenues Increased 45% to $188.1M

August 6, 2014 8:35 am | News | Comments

Impax Laboratories, today reported total revenues increased 45.1% to $188.1 million for the second quarter ended June 30, 2014, compared to $129.6 million in the prior year period.            

Alvogen Acquires Korean Dream Pharma for $187M

August 6, 2014 8:22 am | News | Comments

Alvogen announced today that it has acquired Dream Pharma in South Korea for $187 million in cash. Dream will be acquired through Alvogen’s Asian subsidiaries and, on completion, will create one of the largest generic pharmaceutical companies in South Korea.

Walgreens and Alliance Boots Accelerate Efforts to Fully Combine Both Companies

August 6, 2014 8:07 am | News | Comments

Walgreens today said it has exercised its option to complete the second step of its strategic transaction with Alliance Boots GmbH ahead of the original option period, which was between February and August 2015. The transaction, subject to shareholder and various regulatory approvals, would fully combine the two companies to form the first global pharmacy-led, health and wellbeing enterprise.

Obama Seeks Executive Ways to Limit Tax Inversions

August 5, 2014 5:30 pm | by Josh Lederman - Associated Press - Associated Press | News | Comments

The Obama administration is looking for steps it could take on its own to prevent American companies from reincorporating overseas to shirk U.S. taxes, aiming to sidestep a logjam in Congress, officials said Tuesday. President Barack Obama has denounced so-called tax inversions as unpatriotic and has urged Congress to stop them.

Zoetis Second Quarter Profit Climbs 6.3%

August 5, 2014 11:31 am | by The Associated Press | News | Comments

Zoetis Inc. (ZTS) on Tuesday reported profit that rose by 6.3 percent in its second quarter, and fell short of analysts' expectations. The Florham Park, New Jersey-based company said earnings increased to $136 million, or 27 cents per share, from $128 million, or 26 cents per share, in the same quarter a year ago.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading